Aptus Pharma Ltd (544529) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 544529 | NSE: | Trading | Small Cap

Aptus Pharma Share Price

156 0.00 0.00%
as on 04-Dec'25 16:59

Aptus Pharma Ltd (544529) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 544529 | NSE: | Trading | Small Cap

DeciZen - make an informed investing decision on Aptus Pharma

Based on:

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Aptus Pharma stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
34.53
Market Cap:
107 Cr.
52-wk low:
80.8
52-wk high:
168.4

Is Aptus Pharma Ltd an attractive stock to invest in?

1. Is Aptus Pharma Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Aptus Pharma Ltd is a below average quality company.

2. Is Aptus Pharma Ltd undervalued or overvalued?

The key valuation ratios of Aptus Pharma Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Aptus Pharma Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Aptus Pharma Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Aptus Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Aptus Pharma Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'23Mar'24Mar'25TTM
ROCE % 13.8%26.5%38.2%-
Value Creation
Index
0.00.91.7-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 13.917.924.625
Sales YoY Gr.-28.5%37.5%-
Adj EPS 35.91.34.5
YoY Gr.-100%-78.8%-
BVPS (₹) 6.511.82.829.1
Adj Net
Profit
0.50.93.23
Cash Flow from Ops. -0.2-2.2-1.8-
Debt/CF from Ops. -12.2-2.4-5.6-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NANANA37.5%
Adj EPS NANANA-78.8%
BVPSNANANA-76.3%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'23Mar'24Mar'25TTM
Return on
Equity %
4665.272.328.3
Op. Profit
Mgn %
79.420.1NAN
Net Profit
Mgn %
3.2512.912.6
Debt to
Equity
2.331.5-
Working Cap
Days
01381760
Cash Conv.
Cycle
0851200

Recent Performance Summary

Debt to equity has declined versus last 3 years average to 1.49

Return on Equity has declined versus last 3 years average to 28.30%

Sales growth has been subdued in last 3 years 0.00%

Net Profit has been subdued in last 3 years 0.00%

Sales growth is not so good in last 4 quarters at 0.00%

Latest Financials - Aptus Pharma Ltd.

Standalone Consolidated
TTM EPS (₹) 4.5 -
TTM Sales (₹ Cr.) 24.6 -
BVPS (₹.) 29.1 -
Reserves (₹ Cr.) 13 -
P/BV 5.35 -
PE 34.53 -
From the Market
52 Week Low / High (₹) 80.80 / 168.35
All Time Low / High (₹) 80.80 / 168.35
Market Cap (₹ Cr.) 107
Equity (₹ Cr.) 6.9
Face Value (₹) 10
Industry PE 36.9

Management X-Ray of Aptus Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Aptus Pharma - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Aptus Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'23Mar'24Mar'25
Sales141825
Operating Expenses 131620
Manufacturing Costs001
Material Costs579
Employee Cost 223
Other Costs 777
Operating Profit 125
Operating Profit Margin (%) 4.5%8.7%19.7%
Other Income 000
Interest 000
Depreciation 000
Exceptional Items 000
Profit Before Tax 014
Tax 001
Profit After Tax 013
PAT Margin (%) 1.4%4.5%12.6%
Adjusted EPS (₹)1.35.31.2
Dividend Payout Ratio (%)0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 127
Share Capital 005
Reserves 112
Minority Interest000
Debt259
Long Term Debt243
Short Term Debt017
Trade Payables111
Others Liabilities 224
Total Liabilities 61022

Fixed Assets

Gross Block112
Accumulated Depreciation011
Net Fixed Assets 111
CWIP 000
Investments 000
Inventories237
Trade Receivables236
Cash Equivalents 115
Others Assets 023
Total Assets 61022

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'23Mar'24Mar'25
Cash Flow From Operating Activity -0-2-2
PBT 014
Adjustment 001
Changes in Working Capital -1-3-6
Tax Paid -0-0-1
Cash Flow From Investing Activity -0-0-1
Capex -0-0-1
Net Investments 000
Others 000
Cash Flow From Financing Activity 137
Net Proceeds from Shares 001
Net Proceeds from Borrowing 12-1
Interest Paid -0-0-0
Dividend Paid 000
Others 018
Net Cash Flow 004

Finance Ratio

PARTICULARSMar'23Mar'24Mar'25
Ratios
ROE (%)20.0658.3670.99
ROCE (%)13.7926.4738.22
Asset Turnover Ratio2.282.231.57
PAT to CFO Conversion(x)N/A-2-0.67
Working Capital Days
Receivable Days625866
Inventory Days605877
Payable Days1057354

Aptus Pharma Ltd Stock News

Aptus Pharma Ltd FAQs

The current trading price of Aptus Pharma on 04-Dec-2025 16:59 is ₹156.0.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Dec-2025 the market cap of Aptus Pharma stood at ₹107.0.
The latest P/E ratio of Aptus Pharma as of 03-Dec-2025 is 34.53.
The latest P/B ratio of Aptus Pharma as of 03-Dec-2025 is 5.35.
The 52-week high of Aptus Pharma is ₹168.3 and the 52-week low is ₹80.80.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Aptus Pharma is ₹24.56 ( Cr.) .

About Aptus Pharma Ltd

Aptus Pharma was originally incorporated as ‘Aptus Pharma Private Limited’, as a private limited company under the Companies Act, 1956, with the Registrar of Companies (ROC), Gujarat, pursuant to a Certificate of Incorporation dated August 12, 2010. Subsequently, the company was converted into a public limited company pursuant to a resolution passed by its Shareholders at an extraordinary general meeting held on November 30, 2024 and consequently the name of the company was changed to ‘Aptus Pharma Limited’ and a fresh certificate of incorporation dated December 12, 2024 was issued by the Registrar of Companies, Central Processing Centre.

It is engaged in the business of marketing, and distribution of finished pharmaceutical formulations. It does not own any manufacturing plants but has entered into contract manufacturing agreement with several manufacturing units, under various arrangements. Of these, it has formal loan and license agreements in place with few manufacturing units. The remaining production is carried out through informal arrangements with other manufacturers, based on purchase orders (PO). It provides a diverse range of pharmaceutical products catering to various therapeutic categories including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, etc. These are offered across a variety of dosage forms, such as tablets, capsules, softgels, syrups, suspensions, injections, ointments, creams, balms, drops, lotions, vials, powders, gels, and sachets.

Its manufacturing partners are selected based on stringent quality, compliance, and delivery standards. These manufacturers are required to hold WHO-GMP, Certifications, and are subject to periodic review and audits by its quality assurance team. Before placing purchase orders with its contract manufacturers, it ensures about their certifications, clientele, manufacturing infrastructure, and their delivery capabilities through proper due diligence and proper documentation with regards to defined terms for quality control parameters, packaging standards, lead times, and logistics.

Its quality assurance framework includes real-time lab analysis of every batch during and after manufacturing, with testing conducted at affiliated certified laboratories. It follows established quality control protocols, including compound assay, disintegration, dissolution, stability, friability, uniform drug distribution, and content uniformity tests. 

Business area of the company

The company is engaged in the business of marketing, and distribution of finished pharmaceutical formulations. It operates through a contract manufacturing model. It provides a diverse range of pharmaceutical products catering to various therapeutic categories including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, etc.

Product categories of the company

  • Anti-infectives
  • Antacids & PPI
  • G.I. medicines
  • Anti-allergic and respiratory medicine
  • Nutritional supplements 
  • Anti-inflammatory and pain management
  • Neuro-psychiatric medicine
  • lipid lowering medicine
  • anti-hypertensive & cardiovascular medicine
  • Antidiabetic medicine
  • Consumer care

Awards and accreditation

  • 2017: Best Company in Quality Control 2017 - India 5000 MSME
  • 2019: Best Company in Quality Control Indian Pharma Expo 2019
  • 2020: Chilkul Most Trusted Brand of Region - CIMS Publication & IDR
  • 2021: Business Excellence Pharma & Healthcare - Zee 24
  • 2021: Best Healthcare Brand ‘Chilkul’ - BHB Economic Times 2021
  • 2022: Business excellence award emerging pharma company of Gujarat (IDR CIMS MEDICA 2022)
  • 2023: Promising Entrepreneur of India - Economic Times
  • 2023: Best Healthcare Brand ‘Chilkul’ - BHB Economic Times 2023

History and milestones

  • 2010: Incorporation of the company under the name ‘Aptus Pharma Private Limited’ 
  • 2011-2013: Commenced operations through four regional headquarters in Gujarat. Launched a portfolio of 25 products targeting essential therapeutic segments. 
  • 2013-2016: Achieved around 33% geographical coverage in Gujarat. Expanded product portfolio to over 50 products, catering to both acute and chronic segments. 
  • 2016-2019: Increased portfolio to over 70 products in response to evolving therapeutic requirements. 
  • 2019-2022: Extended presence to around 80% of Gujarat, including remote areas. Product portfolio grew to over 100 products. Appointed a C&F agent in Ahmedabad and improved logistics infrastructure. 
  • 2022-2024: Achieved full geographical coverage across Gujarat. Expanded product portfolio to over 175 products. Established three operational divisions: Acute, Chronic, and OTC. Initiated in-house manufacturing under a loan license arrangement. 
  • 2024: Converted to a public limited company and changed name to ‘Aptus Pharma Limited’.

You have 0 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×